On 25 March 2026, Zylox-Tonbridge Medical Technology Co., Ltd. conducted an on-market buyback of 79,000 H shares on the Hong Kong Stock Exchange, paying between HK$23.56 and HK$24.10 per share. The aggregate consideration totalled HK$1.89 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) fell by 79,000 to 329.15 million. • Treasury shares increased to 7.20 million, while total issued shares remained at 336.35 million. • The repurchased amount represents 0.0234 % of the company’s issued share capital prior to the purchase. • All 79,000 shares are being held as treasury stock; none have been cancelled.

Buybacks are executed under the repurchase mandate approved on 30 May 2025, which authorises Zylox-Tonbridge to repurchase up to 31.96 million shares. Cumulative repurchases under this mandate now stand at 4.39 million shares, or 1.34 % of the company’s issued shares at the mandate date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 24 April 2026.